Intravenous γ-globulin use in children with Kawasaki disease

S. A. Plotkin, R. S. Daum, G. S. Giebink, C. B. Hall, M. Lepow, E. K. Marcuse, G. H. McCracken, C. F. Phillips, G. B. Scott, H. T. Wright, G. Peter, A. R. Hinman, P. Parkman, R. Gold, J. G. Easton

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A recent controlled American trial of treatment for Kawasaki disease compared the use of acetylsalicylic acid (aspirin) alone v aspirin at the same dose plus a single preparation of IV γ-globulin, which is not currently licensed in the United States. The dosage of IV γ-globulin was 400 mg/kg/d for four days, and the dosage of aspirin was 80 to 100 mg/kg/d for as many as 8 weeks. The results indicated that, if administered within ten days of onset of fever, the combined treatment significantly lowered the prevalence of coronary artery dilation and aneurysms detected at 2 and 7 weeks postenrollment. The IV γ-globulin-treated group showed significant and rapid reduction in fever, WBC count, and generalized inflammatory signs. Prior studies in Japan also showed benefit from IV γ-globulin.

Original languageEnglish (US)
Pages (from-to)122
Number of pages1
JournalPediatrics
Volume82
Issue number1
StatePublished - 1988

Fingerprint

Mucocutaneous Lymph Node Syndrome
Globulins
Aspirin
Fever
Coronary Aneurysm
Dilatation
Coronary Vessels
Japan
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Plotkin, S. A., Daum, R. S., Giebink, G. S., Hall, C. B., Lepow, M., Marcuse, E. K., ... Easton, J. G. (1988). Intravenous γ-globulin use in children with Kawasaki disease. Pediatrics, 82(1), 122.

Intravenous γ-globulin use in children with Kawasaki disease. / Plotkin, S. A.; Daum, R. S.; Giebink, G. S.; Hall, C. B.; Lepow, M.; Marcuse, E. K.; McCracken, G. H.; Phillips, C. F.; Scott, G. B.; Wright, H. T.; Peter, G.; Hinman, A. R.; Parkman, P.; Gold, R.; Easton, J. G.

In: Pediatrics, Vol. 82, No. 1, 1988, p. 122.

Research output: Contribution to journalArticle

Plotkin, SA, Daum, RS, Giebink, GS, Hall, CB, Lepow, M, Marcuse, EK, McCracken, GH, Phillips, CF, Scott, GB, Wright, HT, Peter, G, Hinman, AR, Parkman, P, Gold, R & Easton, JG 1988, 'Intravenous γ-globulin use in children with Kawasaki disease', Pediatrics, vol. 82, no. 1, pp. 122.
Plotkin SA, Daum RS, Giebink GS, Hall CB, Lepow M, Marcuse EK et al. Intravenous γ-globulin use in children with Kawasaki disease. Pediatrics. 1988;82(1):122.
Plotkin, S. A. ; Daum, R. S. ; Giebink, G. S. ; Hall, C. B. ; Lepow, M. ; Marcuse, E. K. ; McCracken, G. H. ; Phillips, C. F. ; Scott, G. B. ; Wright, H. T. ; Peter, G. ; Hinman, A. R. ; Parkman, P. ; Gold, R. ; Easton, J. G. / Intravenous γ-globulin use in children with Kawasaki disease. In: Pediatrics. 1988 ; Vol. 82, No. 1. pp. 122.
@article{19862598bb864b419d440f13df3aeeeb,
title = "Intravenous γ-globulin use in children with Kawasaki disease",
abstract = "A recent controlled American trial of treatment for Kawasaki disease compared the use of acetylsalicylic acid (aspirin) alone v aspirin at the same dose plus a single preparation of IV γ-globulin, which is not currently licensed in the United States. The dosage of IV γ-globulin was 400 mg/kg/d for four days, and the dosage of aspirin was 80 to 100 mg/kg/d for as many as 8 weeks. The results indicated that, if administered within ten days of onset of fever, the combined treatment significantly lowered the prevalence of coronary artery dilation and aneurysms detected at 2 and 7 weeks postenrollment. The IV γ-globulin-treated group showed significant and rapid reduction in fever, WBC count, and generalized inflammatory signs. Prior studies in Japan also showed benefit from IV γ-globulin.",
author = "Plotkin, {S. A.} and Daum, {R. S.} and Giebink, {G. S.} and Hall, {C. B.} and M. Lepow and Marcuse, {E. K.} and McCracken, {G. H.} and Phillips, {C. F.} and Scott, {G. B.} and Wright, {H. T.} and G. Peter and Hinman, {A. R.} and P. Parkman and R. Gold and Easton, {J. G.}",
year = "1988",
language = "English (US)",
volume = "82",
pages = "122",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "1",

}

TY - JOUR

T1 - Intravenous γ-globulin use in children with Kawasaki disease

AU - Plotkin, S. A.

AU - Daum, R. S.

AU - Giebink, G. S.

AU - Hall, C. B.

AU - Lepow, M.

AU - Marcuse, E. K.

AU - McCracken, G. H.

AU - Phillips, C. F.

AU - Scott, G. B.

AU - Wright, H. T.

AU - Peter, G.

AU - Hinman, A. R.

AU - Parkman, P.

AU - Gold, R.

AU - Easton, J. G.

PY - 1988

Y1 - 1988

N2 - A recent controlled American trial of treatment for Kawasaki disease compared the use of acetylsalicylic acid (aspirin) alone v aspirin at the same dose plus a single preparation of IV γ-globulin, which is not currently licensed in the United States. The dosage of IV γ-globulin was 400 mg/kg/d for four days, and the dosage of aspirin was 80 to 100 mg/kg/d for as many as 8 weeks. The results indicated that, if administered within ten days of onset of fever, the combined treatment significantly lowered the prevalence of coronary artery dilation and aneurysms detected at 2 and 7 weeks postenrollment. The IV γ-globulin-treated group showed significant and rapid reduction in fever, WBC count, and generalized inflammatory signs. Prior studies in Japan also showed benefit from IV γ-globulin.

AB - A recent controlled American trial of treatment for Kawasaki disease compared the use of acetylsalicylic acid (aspirin) alone v aspirin at the same dose plus a single preparation of IV γ-globulin, which is not currently licensed in the United States. The dosage of IV γ-globulin was 400 mg/kg/d for four days, and the dosage of aspirin was 80 to 100 mg/kg/d for as many as 8 weeks. The results indicated that, if administered within ten days of onset of fever, the combined treatment significantly lowered the prevalence of coronary artery dilation and aneurysms detected at 2 and 7 weeks postenrollment. The IV γ-globulin-treated group showed significant and rapid reduction in fever, WBC count, and generalized inflammatory signs. Prior studies in Japan also showed benefit from IV γ-globulin.

UR - http://www.scopus.com/inward/record.url?scp=0023932233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023932233&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 122

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 1

ER -